The peptide market in the U.S. is experiencing a rapid cryptocurrency renaissance. According to blockchain analytics, in the first quarter of 2026, sellers of these drugs received $32 million in digital assets — a 700% increase compared to the same period last year. This is not just statistics, but a clear signal that cryptocurrencies are moving beyond speculation and becoming a tool for real, albeit gray, transactions.

Peptides, promoted as remedies for weight loss, muscle gain, and rejuvenation, have long been in a gray zone. Approved versions are sold in pharmacies, but a significant portion of online trade bypasses official channels. Cheap drugs are imported from foreign laboratories without prescriptions or insurance, and packaging often bears the label "not for human use." This is where cryptocurrency becomes the ideal payment method.

Why Bitcoin, Not Banks

Banks and payment systems refuse to serve such sellers due to high compliance risks. As a result, many suppliers accept only Bitcoin. Interestingly, for some buyers, this becomes their first experience with cryptocurrencies. For example, a 49-year-old U.S. marketer named Zach, wanting to purchase retatrutide (an Eli Lilly drug), found a Chinese supplier who agreed to ship 20 vials for $240. On the U.S. market, such a purchase would cost him $300 monthly. The seller accepted only digital assets, and Zach had to buy Bitcoin for the first time in his life.

Three Stages of Market Growth

Analysts identify three key stages in the development of this segment. Before 2025, it was a niche "underground" with an inflow of about $200,000 per month. Then the topic came into the spotlight of the Make America Healthy Again movement, coinciding with the appointment of Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Services. A direct causal link is hard to establish, but the coincidence is striking. A sharp surge occurred in late 2025 after the topic entered the TikTok subculture of looksmaxxing, where users are obsessed with improving their appearance. The average monthly inflow quadrupled to $9.9 million, and in peak months exceeded $10 million.

For comparison, a former Coinbase Global employee estimated the annual turnover of the peptide market at $100 million as early as 2023. According to TRM Labs, in 2025, digital asset inflows into the sector reached $41.4 million — a 20% increase year-over-year. TRM Labs' Global Director of Policy, Ari Redbord, compared this dynamic to the early stages of shadow online markets like Silk Road.

Major Players Shift to Stablecoins

The market is uneven: the bulk of the volume comes from a narrow group of large sellers with a broad client base. Small players dabble in various coins, but large suppliers almost exclusively use Bitcoin and stablecoins. Among sellers with an average deposit of $1,000 or more, "stablecoins" dominate — this acts as insurance against exchange rate fluctuations for large and cross-border purchases. The logic of professional participants is clear: Bitcoin's volatility on large volumes can wipe out margins.

The Chinese Connection

The primary raw materials for peptides are produced in China. Chinese chemical manufacturers are actively expanding their presence in this niche. Over the three quarters of last year, imports from China to the U.S. nearly doubled to over $300 million. Some suppliers have transitioned to peptides from the drug trade. For example, the Chinese company Bigreat Technology, which previously supplied fentanyl and amphetamine precursors to Russia and Kazakhstan, set up a separate legal entity — Zhengzhou DEPU Technology — to sell cosmetic peptides.

My conclusion: The peptide market on cryptocurrencies is a classic example of how technology solves the "trust" problem in gray zones. Bitcoin and stablecoins are becoming not just a means of payment, but a bridge between global demand and supply that banks and regulators cannot yet block. However, parallels with Silk Road and drug trafficking suggest that sooner or later, government scrutiny will inevitably intensify.